Diphencyprone (DPCP) for Cutaneous Metastases

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Icahn School of Medicine at Mount Sinai, New York, NY
Cutaneous Metastases+2 More
Diphencyprone (DPCP) - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This is a phase I, open label study employing diphencyprone (DPCP) to characterize gene expression changes of various immune cell and tumor markers in cutaneous metastases treated with topical DPCP twice weekly for 12 weeks in combination with PD-1 or PD-L1 immune checkpoint inhibition (ICI), compared to pre-treatment cutaneous metastases and to describe the adverse events associated with DPCP when administered topically twice weekly for 12 weeks in combination with PD-1 or PD-L1 ICI.

Eligible Conditions

  • Cutaneous Metastases

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: at Day 98 or 128

Day 98
Proportion of subjects with a grade 3 adverse event

Trial Safety

Safety Progress

1 of 3

Trial Design

1 Treatment Group

Diphencyprone (DPCP)
1 of 1
Experimental Treatment

27 Total Participants · 1 Treatment Group

Primary Treatment: Diphencyprone (DPCP) · No Placebo Group · Phase 1

Diphencyprone (DPCP)
Drug
Experimental Group · 1 Intervention: Diphencyprone (DPCP) · Intervention Types: Drug

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: at day 98 or 128
Closest Location: Icahn School of Medicine at Mount Sinai · New York, NY
Photo of icahn school of medicine at mount sinai  1Photo of icahn school of medicine at mount sinai  2Photo of icahn school of medicine at mount sinai  3
1997First Recorded Clinical Trial
1 TrialsResearching Cutaneous Metastases
529 CompletedClinical Trials

Eligibility Criteria

Age 18+ · All Participants · 6 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have cancer and at least three cutaneous metastasis sites that can be biopsied.
Subjects are being treated with PD-1 or PD-L1 ICI therapy, but are not taking part in this study.
You are able to understand the information you are being asked to give

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.